Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $180.85 | 9 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $146.34 | 7 | $0 (2023) |
| GlaxoSmithKline, LLC. | $18.80 | 1 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $15.71 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $42.53 | 2 | ABBVIE INC. ($42.53) |
| 2022 | $74.77 | 4 | ABBVIE INC. ($59.06) |
| 2021 | $44.75 | 2 | AbbVie Inc. ($44.75) |
| 2019 | $18.80 | 1 | GlaxoSmithKline, LLC. ($18.80) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/29/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/06/2023 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/07/2022 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $15.71 | General |
| Category: CARDIOVASCULAR | ||||||
| 08/17/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.09 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/30/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.69 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/03/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $20.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/14/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $23.63 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/28/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $21.12 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/12/2019 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 323 | 593 | $66,659 | $43,486 |
| 2022 | 7 | 248 | 445 | $51,719 | $30,458 |
| 2021 | 7 | 307 | 583 | $49,726 | $35,447 |
| 2020 | 6 | 185 | 347 | $33,331 | $23,440 |
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 125 | 358 | $32,582 | $21,735 | 66.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 61 | 62 | $13,076 | $7,714 | 59.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 64 | $8,733 | $5,863 | 67.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 47 | 50 | $6,779 | $4,461 | 65.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 54 | 59 | $5,489 | $3,714 | 67.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 87 | 242 | $21,415 | $13,388 | 62.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 38 | 40 | $10,514 | $5,551 | 52.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 73 | $9,917 | $5,349 | 53.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 27 | 27 | $3,603 | $2,228 | 61.8% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 29 | 29 | $2,645 | $1,626 | 61.5% |
| 99226 | Follow-up observation care per day, typically 35 minutes | Facility | 2022 | 13 | 16 | $2,027 | $1,294 | 63.8% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 18 | 18 | $1,599 | $1,023 | 63.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 123 | 302 | $23,383 | $16,878 | 72.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 30 | 30 | $6,649 | $4,719 | 71.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 51 | 53 | $6,133 | $4,487 | 73.2% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 44 | 128 | $5,398 | $3,546 | 65.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 26 | 37 | $4,117 | $2,961 | 71.9% |
| 99220 | Hospital observation care, typically 70 minutes | Facility | 2021 | 11 | 11 | $2,271 | $1,593 | 70.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 22 | 22 | $1,775 | $1,263 | 71.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 74 | 216 | $17,436 | $12,652 | 72.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 30 | 30 | $7,050 | $4,684 | 66.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2020 | 23 | 24 | $2,798 | $2,078 | 74.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 24 | 24 | $2,256 | $1,412 | 62.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $2,064 | $1,340 | 64.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 21 | 40 | $1,727 | $1,276 | 73.9% |
About Dr. Vikas Lall, MD
Dr. Vikas Lall, MD is a Internal Medicine healthcare provider based in Roseburg, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/20/2008. The National Provider Identifier (NPI) number assigned to this provider is 1922265784.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Vikas Lall, MD has received a total of $180.85 in payments from pharmaceutical and medical device companies, with $42.53 received in 2023. These payments were reported across 9 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($180.85).
As a Medicare-enrolled provider, Lall has provided services to 1,063 Medicare beneficiaries, totaling 1,968 services with total Medicare billing of $132,831. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Roseburg, OR
- Active Since 05/20/2008
- Last Updated 06/22/2017
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1922265784
Products in Payments
- DALVANCE (Drug) $146.34
- TRELEGY ELLIPTA (Drug) $18.80
- ENTRESTO (Drug) $15.71
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Roseburg
William Townsend, Md, MD
Internal Medicine — Payments: $3,059
Dr. Mohamed Abdel Khalek, M.d, M.D
Internal Medicine — Payments: $1,602
Lorrie Oksenholt, Do, DO
Internal Medicine — Payments: $1,576
Joel Lee, Md, MD
Internal Medicine — Payments: $1,275
Doru Totoian, Md, MD
Internal Medicine — Payments: $1,266
Dr. Hennie Abrio, Md, MD
Internal Medicine — Payments: $970.03